Clinical Trial Update: Study of Ataluren (PTC124) in Nonambulatory Participants With Nonsense-Mutation-Mediated Duchenne/Becker Muscular Dystrophy (nmDMD/BMD) [Phase 2]

View source ↗

Summary

Phase 2 trial update for Ataluren (PTC124) in nonambulatory Duchenne/Becker muscular dystrophy due to nonsense mutations; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Becker Muscular Dystrophy
• Duchenne Muscular Dystrophy

Drugs mentioned

• ataluren (ataluren)

Snippet

Sponsor: PTC Therapeutics | Conditions: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy | Phase 2 | Status: TERMINATED | Results posted: 2020-07-29